Soligenix Advances SGX302 Psoriasis Treatment with Promising Early Trial Results

Soligenix Inc. (NASDAQ: SNGX) is advancing its phase 2a clinical trial of SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis, building on promising phase 1/2 data. Early results from the trial show encouraging signs of safety and biological activity, highlighting SGX302's potential as a novel, well-tolerated treatment for a chronic autoimmune skin condition affecting millions globally. The company's progress with SGX302 represents a strategic expansion into the dermatology market, leveraging its experience with hypericin-based therapies.

The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the company's first-in-class innate defense regulator technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and SGX945 in Behçet's disease.

Soligenix aims to address a significant market opportunity projected to reach $67 billion by 2030 while expanding its dermatology presence. Ongoing trial results could pave the way for larger studies, regulatory guidance, and commercialization. The company's Public Health Solutions business segment includes development programs for RiVax, its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses such as Marburg and Ebola and CiVax, the company's vaccine candidate for the prevention of COVID-19 caused by SARS-CoV-2.

The development of Soligenix's vaccine programs incorporates the use of its proprietary heat stabilization platform technology known as ThermoVax. To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency and the Biomedical Advanced Research and Development Authority. For further information about the company's broader development pipeline, visit https://www.Soligenix.com. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.